Sethera Therapeutics, Inc.
Biotechnology company developing an enzymatic platform for synthesis and discovery of polymacrocyclic peptides. The platform uses radical S-adenosyl-L-methionine (radical SAM) maturase-based biocatalysis to install thioether linkages and generate diverse, stable macrocyclic architectures. The organization supports partner collaborations for library construction, target screening, and late-stage enzymatic peptide modification, and publishes peer-reviewed research and patents describing the underlying enzymology and applications.
Industries
N/A
Services
Polymacrocyclic peptide library generation and screening support
Design and enzymatic construction of polymacrocyclic peptide libraries and support for compatibility with phage, mRNA display and DNA-encoded library screening; pooling and sequencing workflows for hit identification.
Late-stage enzymatic macrocyclization for peptide optimization
Application of sequence-agnostic enzymatic macrocyclization methods to convert linear peptide candidates into stabilized macrocyclic forms for therapeutic development.
Polymacrocyclic peptide library generation and screening support
Design and enzymatic construction of polymacrocyclic peptide libraries and support for compatibility with phage, mRNA display and DNA-encoded library screening; pooling and sequencing workflows for hit identification.
Late-stage enzymatic macrocyclization for peptide optimization
Application of sequence-agnostic enzymatic macrocyclization methods to convert linear peptide candidates into stabilized macrocyclic forms for therapeutic development.
Expertise Areas
- Polymacrocyclic peptide discovery
- Enzymatic peptide macrocyclization
- Biocatalysis and enzyme engineering
- Macrocycle library construction and display screening
Key Technologies
- Radical S-adenosyl-L-methionine (radical SAM) enzymatic macrocyclization
- Thioether ligation
- Noncanonical amino acid incorporation
- Combinatorial macrocycle library construction